Vitamin D3 Supplementation Has No Effect on Conventional Cardiovascular Risk Factors: A Parallel-Group, Double-Blind, Placebo-Controlled RCT

被引:141
|
作者
Wood, Adrian D. [1 ]
Secombes, Karen R. [1 ]
Thies, Frank [1 ]
Aucott, Lorna [1 ]
Black, Alison J. [2 ]
Mavroeidi, Alexandra
Simpson, William G.
Fraser, William D. [3 ]
Reid, David M. [1 ]
Macdonald, Helen M. [1 ]
机构
[1] Univ Aberdeen, Sch Med & Dent, Aberdeen AB25 2ZD, Scotland
[2] Woolmanhill Hosp, Grampian Osteoporosis Serv, Aberdeen AB25 1LD, Scotland
[3] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England
来源
关键词
IMPAIRED GLUCOSE-TOLERANCE; ALL-CAUSE MORTALITY; LONG-TERM TREATMENT; BLOOD-PRESSURE; 25-HYDROXYVITAMIN D; 1,25-DIHYDROXYVITAMIN D-3; DISEASE MORTALITY; CONTROLLED-TRIAL; D ALPHACALCIDOL; HEALTH;
D O I
10.1210/jc.2012-2126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Observational studies show an association between low vitamin D status assessed by circulating 25-hydroxyvitamin D and cardiovascular events and mortality. Data from randomized controlled trials are limited. Objective: The aim of this study was to test whether daily doses of vitamin D-3 at 400 or 1000 IU/d for 1 yr affected conventional markers of cardiovascular disease (CVD) risk. Design: We conducted a parallel-group, double-blind, placebo-controlled randomized controlled trial. Randomization was computer generated. Participants and study investigators were blinded to intervention groupings throughout the trial. Setting: The study was conducted at the Clinical Research Facility, University of Aberdeen, United Kingdom. Participants: A total of 305 healthy postmenopausal women aged 60-70 yr were recruited for the study. Intervention: Each woman received a daily capsule of 400 or 1000 IU vitamin D-3 or placebo randomly allocated. Main Outcome Measures: Primary outcomes were serum lipid profile [total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B-100], insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, soluble intracellular adhesion molecule-1), and blood pressure. Results: A total of 265 (87%) participants completed all study visits. Small differences between groups for serum apolipoprotein B-100 change [repeated measures ANOVA, P = 0.04; mean(SD), -1.0 (10.0) mg/dl (400 IU); -1.0 (10.0) mg/dl (1000 IU); and +0.02 (10.0) mg/dl (placebo)] were not considered clinically significant. Other systemic markers for CVD risk remained unchanged. There was significant seasonal variation in systolic and diastolic blood pressure independent of vitamin D dose (P < 0.001, linear mixed model). Mean (SD) reduction in systolic blood pressure from winter to summer was -6.6 (10.8) mmHg. Conclusions: Improving vitamin D status through dietary supplementation is unlikely to reduce CVD risk factors. Confounding of seasonality should be recognized and addressed in future studies of vitamin D. (J Clin Endocrinol Metab 97: 3557-3568, 2012)
引用
收藏
页码:3557 / 3568
页数:12
相关论文
共 50 条
  • [1] Vitamin D-3 Supplementation Has No Effect on Conventional Cardiovascular Risk Factors: A Parallel-Group, Double-Blind, Placebo-Controlled RCT
    Plank, J.
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2013, 6 (01): : 42 - 44
  • [2] A Randomized Double-Blind Placebo-Controlled Trial of the Effect of Vitamin D3 Supplementation on Breast Density in Premenopausal Women
    Brisson, Jacques
    Berube, Sylvie
    Diorio, Caroline
    Masse, Benoit
    Lemieux, Julie
    Duchesne, Thierry
    Delvin, Edgar
    Vieth, Reinhold
    Yaffe, Martin J.
    Chiquette, Jocelyne
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (08) : 1233 - 1241
  • [3] Omega-3 supplementation in young offenders: a randomized, stratified, double-blind, placebo-controlled, parallel-group trial
    Raine, Adrian
    Leung, Chi-Ching
    Singh, Melvinder
    Kaur, Jasmin
    [J]. JOURNAL OF EXPERIMENTAL CRIMINOLOGY, 2020, 16 (03) : 389 - 405
  • [4] Omega-3 supplementation in young offenders: a randomized, stratified, double-blind, placebo-controlled, parallel-group trial
    Adrian Raine
    Chi-Ching Leung
    Melvinder Singh
    Jasmin Kaur
    [J]. Journal of Experimental Criminology, 2020, 16 : 389 - 405
  • [5] Oral vitamin D3 supplementation for chronic plaque psoriasis: a randomized, double-blind, placebo-controlled trial
    Ingram, Michelle A.
    Jones, M. Beatrix
    Stonehouse, Welma
    Jarrett, Paul
    Scragg, Robert
    Mugridge, Owen
    von Hurst, Pamela R.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (07) : 648 - 657
  • [6] Effect of vitamin D3 supplementation on insulin resistance and β-cell function in prediabetes: a double-blind, randomized, placebo-controlled trial
    Wallace, Helen J.
    Holmes, Lauren
    Ennis, Cieran N.
    Cardwell, Christopher R.
    Woodside, Jayne V.
    Young, Ian S.
    Bell, Patrick M.
    Hunter, Steven J.
    McKinley, Michelle C.
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2019, 110 (05): : 1138 - 1147
  • [7] Effect of Oral Vitamin D3 Supplementation in Exclusively Breastfed Newborns: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
    Lin, Chao-Hsu
    Lin, Chien-Yu
    Sung, Yi-Hsiang
    Li, Sung-Tse
    Cheng, Bi-Wen
    Weng, Shun-Long
    Chang, Shing-Jyh
    Lee, Hung-Chang
    Lee, Yann-Jinn
    Ting, Wei-Hsin
    Chang, Hung-Yang
    Wu, Yi-Lei
    Lin, Chih-Sheng
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (04) : 786 - 793
  • [8] A randomized, double-blind, placebo-controlled of vitamin D3 for Irish children with asthma
    Kerley, C. P.
    Hutchinson, Katrina
    Greally, P.
    Coghlan, D.
    Elnazir, B.
    [J]. PROCEEDINGS OF THE NUTRITION SOCIETY, 2015, 74 (OCE4) : E213 - E213
  • [9] A randomized, double-blind, placebo-controlled of vitamin D3 for Irish children with asthma
    Kerley, C. P.
    Hutchinson, Katrina
    Greally, P.
    Coghlan, D.
    Elnazir, B.
    [J]. PROCEEDINGS OF THE NUTRITION SOCIETY, 2014, 73 (OCE2) : E55 - E55
  • [10] Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
    Fiona Gaughran
    Dominic Stringer
    Michael Berk
    Shubulade Smith
    David Taylor
    Eromona Whiskey
    Sabine Landau
    Robin Murray
    Philip McGuire
    Poonam Gardner-Sood
    Gabriella Wojewodka
    Simone Ciufolini
    Harriet Jordan
    Jessie Clarke
    Lauren Allen
    Amir Krivoy
    Brendon Stubbs
    Philippa Lowe
    Maurice Arbuthnott
    Shanaya Rathod
    Andrew Boardman
    Mudasir Firdosi
    John J. McGrath
    [J]. Trials, 21